Skin disease Archives

Best in Biotech 23 Aug 2023

Latest advancements in psoriasis research over the past year

Psoriasis, an autoimmune condition that causes flaky patches of skin to form scales, occurs when the body’s immune system attacks its own healthy skin cells. And because people with psoriasis…

August 23, 2023 - 8 minutesmins - By Roohi Mariam Peter

News and Trends 23 Mar 2023

Intracellular “smoke detector” discovery has skin disease therapy implications

A study by the University of Bonn in Germany could lead to therapies against skin and intestinal diseases in the medium term.Researchers at the universities of Bonn and Singapore have…

March 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

Dupixent gets EU nod for children with severe atopic dermatitis

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent (dupilumab), recommending expanded approval in the European Union (EU) to treat severe…

January 27, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 4 Jan 2023

Aditxt forms Adimune to focus on immune modulation therapies

Aditxt, Inc., a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has formed a U.S.-based subsidiary Adimune, Inc. The plan is…

January 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Dupilumab…

December 15, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 30 Nov 2022

TrialSpark acquires immunodermatology portfolio and creates Libertas Bio

TrialSpark has announced the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology assets from Asana BioSciences. The Libertas Bio pipeline now includes…

November 30, 2022 - 3 minutesmins - By Jim Cornall

RDEB recessive dystrophic epidermolysis bullosa skin blisters

News and Trends 21 Nov 2022

New Replay HSV gene therapy company Telaria to focus on skin diseases

Replay has announced the launch of Telaria, a herpes simplex virus (HSV) gene therapy company targeting rare skin diseases. It is the second of Replay’s product companies to leverage its…

November 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

A new treatment for tackling epidermolysis bullosa

By Jordi Casals, president, EMEA, Amryt Pharma Epidermolysis bullosa (EB), sometimes described as “the worst disease you’ve never heard of,” is a group of rare and distressing inherited skin disorders…

November 14, 2022 - 3 minutesmins - By External Contributor

News and Trends 11 Nov 2022

Prurigo nodularis treatment recommended for EU approval

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent (dupilumab) in the European Union (EU) to treat…

November 11, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Incyte to acquire Medicxi-backed Villaris Therapeutics to tackle vitiligo

Incyte has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. The deal…

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Sep 2022

Treatment for adults with chronic skin condition approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. Dupilumab is being jointly developed by Sanofi and Regeneron under…

September 29, 2022 - 4 minutesmins - By Liza Laws

News and Trends 19 Sep 2022

Kamari Pharma raises $8M in investment for development of drugs for skin diseases

An $8 million investment has been raised by Kamari Pharma following investment from the Guangzhou-Israel Biotechnology Fund (GIBF) that creates added value for Israeli, European and American companies looking to…

September 19, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Sep 2022

Regeneron and Sanofi announce published trial results in children with dermatitis

Positive results from a phase 3 trial in children aged 6 months to five years old with uncontrolled moderate-to-severe dermatitis have been published. Regeneron Pharmaceuticals, Inc. and Sanofi made the…

September 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Sep 2022

Ilya Pharma partners with US Defense Department for wound healing drug

A drug to accelerate wound healing and reduced scar volume has had a major breakthrough shown in results from a first in human trial. Ilya Pharma, a clinical stage immunotherapy…

September 13, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Sep 2022

Treatment for adults with moderate to severe psoriasis approved by FDA

A treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy has been approved by the U.S. Food and Drug Administration (FDA). Bristol Myers Squibb…

September 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Sep 2022

Lutris Pharma radiation trial brings positive results for breast cancer patients

Top line results from a clinical trial treating breast cancer patients with radiation dermatitis (RD) have been positive. Lutris Pharma, based in Israel, is a biopharma company focused on improving…

September 8, 2022 - 4 minutesmins - By Liza Laws

News and Trends 2 Sep 2022

Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug

More than half of patients treated for psoriasis with an intravenous injection showed no visible pustules just one week after receiving treatment. Boehringer Ingelheim announced today (September 2) that the…

September 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 25 Aug 2022

Ilya Pharma finalizes global patent coverage for modified lactic acid bacteria to treat wounds

Ilya Pharma, a Swedish clinical stage biopharma company focused on delivering local immunotherapies to patients, has announced the issue of four new patents. These are: one in India, and continuation…

August 25, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Aug 2022

Treatment for patients with fragile skin disease accepted by FDA

The U.S. Food and Drug Administration (FDA) has accepted the filing of a biologic license application (BLA) for B-VEC, a treatment for patients with dystrophic epidermolysis bullosa (DEB). Krystal Biotech…

August 19, 2022 - 3 minutesmins - By Liza Laws

News and Trends 21 Jul 2022

Almirall launches new call to find innovative therapies for skin diseases

A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A. This is the seventh call through AlmirallShare – an open…

July 21, 2022 - 3 minutesmins - By Liza Laws

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering